PARIS – Miracor Medical SA secured a $28 million series E funding round for its Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) impulse system, intended for treating patients presenting with ST-Elevation Myocardial Infarction (STEMI). “This funding will be used to move the PiCSO clinical trial program forward, and to begin distributing our technology in Europe,” Olivier Delporte, CEO of Miracor, told BioWorld.

Ionpath Inc., a developer of high-definition spatial proteomics, scored $18 million in a series B funding round led by Samsara Biocapital. The round also included global mass spectrometry leader Bruker Corp. as a new investor. Menlo Park, Calif.-based Ionpath plans to use the investment for continued development and deployment of the company’s Multiplexed Ion Beam Imaging (MIBI) technology, which provides quantitative protein imaging at a subcellular level.

HONG KONG – Seoul, South Korea-based Vuno Inc. reported that it plans to list on South Korea’s Kosdaq bourse either by the end of 2020 or early next year, CTO and cofounder Kyu-hwan Jung told the 2020 Bioplus Interphex Korea Conference. After receiving A ratings in the recent technology evaluations by assessment institutions NICE D&B and Korea Enterprise Data, Vuno submitted a preliminary examination application to the bourse on July 28 that is currently underway, the company said.